2015
Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil
Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD. Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 152-161. PMID: 25415289, PMCID: PMC4294967, DOI: 10.1097/qai.0000000000000426.Peer-Reviewed Original ResearchConceptsGenotype resistance testingART initiationAntiretroviral treatmentART costsGenotype testingEvandro Chagas Clinical Research InstituteResistance prevalenceFirst-line ART initiationHIV Clinical CohortHIV treatment guidelinesIncremental cost-effectiveness ratioBaseline patient characteristicsEffective antiretroviral treatmentART-naive individualsLife expectancyClinical Research InstituteCost-effectiveness ratioImmune recoveryCD4 countViral suppressionHIV diseasePatient characteristicsTreatment guidelinesMean agePrimary resistance
2010
Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis
Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA, Investigators F. Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. PLOS Medicine 2010, 7: e1000382. PMID: 21209794, PMCID: PMC3014084, DOI: 10.1371/journal.pmed.1000382.Peer-Reviewed Original ResearchConceptsHIV treatment guidelinesART initiationTreatment guidelinesStage III/IV diseaseLong-term survival advantageEarly antiretroviral therapy initiationAntiretroviral therapy initiationLife expectancySouth African HIVResource limited settingsProjected life expectancyResource-limited settingsGreater life expectancyART regimensTherapy initiationAfrican HIVGuideline componentsSurvival advantageWHO recommendationsTenofovirRegimensStavudineSurvivalGuidelinesInitiation
2009
When to start antiretroviral therapy in resource-limited settings.
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Annals Of Internal Medicine 2009, 151: 157-66. PMID: 19620143, PMCID: PMC3092478, DOI: 10.7326/0003-4819-151-3-200908040-00138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAnti-Infective AgentsCD4 Lymphocyte CountCohort StudiesComputer SimulationCost-Benefit AnalysisDecision TreesDisease ProgressionDrug Administration ScheduleHealth Care CostsHIV InfectionsHumansLife ExpectancySensitivity and SpecificitySouth AfricaTrimethoprim, Sulfamethoxazole Drug CombinationConceptsAntiretroviral therapyCD4 countLong-term survivalCells/LART initiationCells/L.ART initiation strategiesIncremental cost-effectiveness ratioSevere opportunistic diseaseDoris Duke Charitable FoundationLife expectancyCD4 count thresholdHIV treatment decisionsCost-effectiveness ratioInternational clinical trialsBase-case analysisResource-limited settingsYears of lifeCost-effectiveness analysisPerson's life expectancyObservational cohortCD4 thresholdHIV diseaseTreatment guidelinesEarly therapy